ANI Pharmaceuticals to Discuss Q4 and Full Year 2025 Results

The company will host a conference call on February 27, 2026 to discuss its financial results.

Published on Feb. 13, 2026

Got story updates? Submit your updates here. ›

ANI Pharmaceuticals, Inc. announced that it will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the market open. The company's President and CEO, CFO, and Head of Rare Disease will host a conference call that day at 8:00 a.m. ET to discuss the results.

Why it matters

As a diversified biopharmaceutical company, ANI's quarterly and annual financial performance is closely watched by investors and analysts to gauge the company's growth, profitability, and strategic direction across its Rare Disease, Generics, and Brands business units.

The details

ANI Pharmaceuticals will report its Q4 and full year 2025 financial results on February 27, 2026 before the market opens. The company will then host a conference call at 8:00 a.m. ET that same day, with participation from its top executives to discuss the results in detail.

  • ANI will release its Q4 and full year 2025 financial results on Friday, February 27, 2026.
  • The company will host a conference call at 8:00 a.m. ET on February 27, 2026 to discuss the results.

The players

Nikhil Lalwani

President and Chief Executive Officer of ANI Pharmaceuticals.

Stephen P. Carey

Senior Vice President, Finance, and Chief Financial Officer of ANI Pharmaceuticals.

Chris Mutz

Head of Rare Disease at ANI Pharmaceuticals.

ANI Pharmaceuticals, Inc.

A diversified biopharmaceutical company committed to developing, manufacturing, and commercializing innovative and high-quality therapeutics.

Got photos? Submit your photos here. ›

What’s next

Investors and analysts will be closely watching ANI's Q4 and full year 2025 financial results and conference call for insights into the company's performance and outlook.

The takeaway

ANI Pharmaceuticals' upcoming earnings report and call will provide an important update on the company's progress across its key business units as it continues to execute on its mission of 'Serving Patients, Improving Lives' through innovative pharmaceutical products.